A cornerstone of modern neurotoxicology is the testing models. In this regard, considerable efforts have been made to develop robust, high-throughput, and precise neurotoxicity testing models. Creative Biolabs delves into the recent advances in the establishment of these models. Our researchers and scientists have been at the forefront of developing novel and sophisticated models for neurotoxicity testing.
Services | What We Do | Advantages |
---|---|---|
Neurotoxicity Screening Service | Based on our extensive experience in stem cell and genome editing technologies, we can provide new neurotoxicity screening services for CNS drug discovery. We offer a range of iPSC-derived neuronal lineage cells for your project, and we can also reprogram and differentiate iPSC cells from your samples. The general screening process consists of a 3-step process that includes generation of cell lines from iPSCs, differentiation of neural cells, and disease modeling and neurotoxicity screening. For your specific needs, we can also customize the program. |
|
STEMOD™ Neuroscience Ex Vivo Models Services | Based on our advanced neuroscience platform, STEMOD™ neuroscience ex vivo models can be generated from cells, transgenic mice, aged rats and mice. For different research purposes, we can provide services including but not limited to: custom neural differentiation services, custom brain spheroids, custom brain organoid services, custom CNS disease modeling services, blood-brain barrier models. |
|
STEMOD™ Advanced Drug Discovery Service | We develop integrated technology platforms to provide one-stop CNS drug discovery services, including studies on BBB transport and distribution in the brain. |
|
Traditionally, rodents have been the preferred species for in vivo neurotoxicity testing due to their close physiological similarity to humans. However, rodents fall short in time and cost-effectiveness, urging researchers to look for alternative in vivo models. Zebrafish have emerged as promising candidates.
Due to the ethical restrictions and practical limitations of in vivo testing, in vitro models have gained traction, promising rapid and cost-efficient results. These models have been designed to assess the cellular and molecular mechanisms underlying neurotoxicity.
Models | Examples | Advantages |
---|---|---|
3D Cell Culture Models |
|
|
iPSC-Derived Models |
|
|
Microfluidic Platforms |
|
|
In addition, a number of technological advances have complemented experimental work in neurotoxicity testing. These techniques further improve the accuracy and efficiency of in vitro models.
Complementing these biological models, remarkable advancements have been made in computational neurotoxicity testing. In silico models, built on vast databases of neurotoxicants and robust machine learning algorithms, can now predict the neurotoxic potential of untested substances swiftly and accurately. From simple quantitative structure-activity relationship (QSAR) models to more complex deep learning systems, computational models are continually becoming more sophisticated and precise.
Future trends in neurotoxicity testing are directed towards increasing the relevance and predictability of these models to human physiology, reducing animal usage, and exploring higher-throughput techniques.
The future of neurotoxicity testing will likely involve more realistic in vitro systems mimicking complex 3D neuronal connections and diversity, high-throughput applications, the use of nanotechnologies, and more sophisticated computational models.Moreover, more predictive and improved models for chronic neurotoxicities, neurodevelopmental disorders, and neurodegenerative diseases are urgently needed. Better understanding neurotoxicity and its mechanisms requires comprehensive experimental approaches, innovative technologies, and multidisciplinary collaborations among scientists in toxicology, neuroscience, molecular biology, pharmacology, and computer science.
Adopting a combined approach, integrating in vitro, in vivo, and in silico methods, holds the future for neurotoxicity testing. Such complementary use promises to streamline the CNS drug discovery process and expedite the development of safer and more effective therapeutics.
Creative Biolabs continues to lead the way in neurotoxicity testing by utilizing emerging technologies to further refine and enhance neurotoxicity testing models.
For Research Use Only. Not For Clinical Use.